If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.